MADRID – Compared with secukinumab, guselkumab treatment appears to be more effective for patients with plaque psoriasis and self-reported psoriatic arthritis (PsA), according to study results presented at the 2019 European League Against Rheumatism (EULAR) Congress, held June 12-15, in Madrid, Spain.

Using data from the ECLIPSE study (ClinicalTrials.gov identifier: NCT03090100), researchers conducted a post hoc analysis examining treatment outcomes in a subgroup of patients with self-reported PsA.

Participants in this randomized, double-blind study had moderate-to-severe plaque psoriasis. Treatment methods included either guselkumab 100 mg at baseline, week 4, and every 8 weeks thereafter through week 44, or secukinumab 300 mg at baseline, weeks 1 through 4, and every 4 weeks thereafter through week 44.

In patients with self-reported PsA, the primary end point (Psoriasis Area and Severity Index [PASI] 90 at week 48) was achieved by 82.5% and 63.3% of patients in the guselkumab and secukinumab groups, respectively (treatment difference 19.2%; 95% CI, 5-33.4).


Continue Reading

Beyond week 20, patients being treated with guselkumab maintained PASI 90 response; those being treated with secukinumab experienced a response reduction through week 48.

In the overall study population, the primary end point (PASI 75 response at weeks 12 and 48) demonstrated the noninferiority of guselkumab vs secukinumab (84.6% vs 80.2%; P <.001) but superiority was not demonstrated (P =.062). Between the overall study population and the PsA subgroup, adverse events were “generally consistent with the established safety profiles” of both drugs.

Related Articles

“In the subset of patients with self-reported PsA…[guselkumab] demonstrated better maintenance of response and higher efficacy at approximately 1 year compared with [secukinumab],” the researchers of the study concluded. “These findings were consistent with those for the overall study population of patients with plaque [psoriasis].”

Disclosure: This study was sponsored by Janssen Research & Development, LLC. Multiple authors are employee of Janssen Research & Development, LLC. See the reference for complete disclosure information.

Reference

Merola JF, Shu L, Hsu M-C, et al. Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported psoriatic arthritis in the randomized, double-blind, head-to-head comparison study ECLIPSE over 1 year. Presented at: European League Against Rheumatism (EULAR) Congress 2019; June 12-15, 2019; Madrid, Spain. Abstract SAT0390.

This article originally appeared on Rheumatology Advisor